Mural Oncology Aktie News

WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares...

Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a)   Full name of discloser: Mural Oncology plc (b)   Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of n...

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 1...

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentat...

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma